Literature DB >> 19481397

Evaluation of angiogenesis in colorectal carcinoma with multidetector-row CT multislice perfusion imaging.

Shi-Ting Feng1, Can-Hui Sun, Zi-Ping Li, Henry Ka-Fung Mak, Zhen-Peng Peng, Huan-Yi Guo, Quan-Fei Meng.   

Abstract

To evaluate the correlation between 64 multidetector-row CT (64MDCT) perfusion imaging in colorectal carcinoma and microvessel density (MVD) and vascular endothelial growth factor (VEGF), 64MDCT perfusion imaging was performed in 33 patients with pathologically verified colorectal carcinoma. These images were analyzed with perfusion functional software, and time-density curves (TDC) were created for the region of interest (ROI) encompassing the tumor, the target artery and vein. The individual perfusion maps generated indicated blood flow (BF), blood volume (BV), mean transit time (MTT), and permeability-surface area product (PS). MVD and VEGF were evaluated by immunohistochemical staining with anti-CD34 and anti-VEGF, respectively. Correlations between MVD or VEGF with CT perfusion parameters and clinicopathological factors (Dukes' stages, invasion depth, and lymph node and liver metastasis) were also investigated. MVD in the colorectal carcinoma was 22.61+/-9.01 per x200 field. The scores obtained for VEGF expression were 4.15+/-1.09. VEGF staining was positive in 25 of 29 tumors (86.2%). There was no significant correlation between the presence of MVD, VEGF expression and clinicopathological factors (P>0.05). There was also no correlation between MVD, VEGF expression, and any dynamic CT parameters (P>0.05). The BV and MTT were significantly higher in tumors demonstrating serous coat invasion than in those without it (t=-2.63, -2.24, P=0.0137, 0.0331, respectively). BV was also significantly correlated with tumor size (r=0.41, P=0.02). Neither BF nor PS was correlated with clinicopathological factors. In conclusion, 64MDCT perfusion imaging, MVD, and VEGF may reflect angiogenic activity, but no significant correlation among these factors. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19481397     DOI: 10.1016/j.ejrad.2009.04.058

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  6 in total

1.  Integrated ¹⁸F-FDG PET/perfusion CT for the monitoring of neoadjuvant chemoradiotherapy in rectal carcinoma: correlation with histopathology.

Authors:  Michael A Fischer; Bart Vrugt; Hatem Alkadhi; Dieter Hahnloser; Thomas F Hany; Patrick Veit-Haibach
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-24       Impact factor: 9.236

2.  Whole-tumour CT-perfusion of unresectable lung cancer for the monitoring of anti-angiogenetic chemotherapy effects.

Authors:  F Fraioli; M Anzidei; G Serra; S Liberali; A Fiorelli; F Zaccagna; F Longo; M Anile; C Catalano
Journal:  Br J Radiol       Date:  2013-08-01       Impact factor: 3.039

3.  Assessment of the metabolic flow phenotype of primary colorectal cancer: correlations with microvessel density are influenced by the histological scoring method.

Authors:  Vicky Goh; Manuel Rodriguez-Justo; Alec Engledow; Manu Shastry; Raymondo Endozo; Jacqui Peck; Marie Meagher; Stuart A Taylor; Steve Halligan; Ashley M Groves
Journal:  Eur Radiol       Date:  2012-04-18       Impact factor: 5.315

4.  Contrast-enhanced ultrasonography of cervical carcinoma: perfusion pattern and relationship with tumour angiogenesis.

Authors:  Wei Zheng; Yong-Hong Xiong; Jing Han; Zhi-Xing Guo; Yu-Hong Li; An-Hua Li; Xiao-Qing Pei
Journal:  Br J Radiol       Date:  2016-06-24       Impact factor: 3.039

Review 5.  Perfusion CT imaging of colorectal cancer.

Authors:  V Goh; R Glynne-Jones
Journal:  Br J Radiol       Date:  2014-02       Impact factor: 3.039

6.  Evaluation of Angiogenesis and Pathological Classification of Extrahepatic Cholangiocarcinoma by Dynamic MR Imaging for E-Healthcare.

Authors:  Jinyun Tan; Xijun Sun; Shaoyu Wang; Baoqin Ma; Zhaohui Chen; Yaowei Shi; Li Zhang; Mohd Asif Shah
Journal:  J Healthc Eng       Date:  2021-10-11       Impact factor: 2.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.